RASSF1 and cutaneous melanoma: After we used the Kaplan-Meier method to analyze the relationship between RASSF1A gene promoter methylation and the prognosis of patients with skin cutaneous melanoma, we found that the HR was 0.94 (95% CI = [0.69; 1.27], P = 0.694) for the DFS (Fig 4A) and 0.74 (95% CI = [0.53; 1.05], P = 0.106) for the OS (Fig 4B), which suggests that no significant difference existed between RASSF1A gene promoter methylation and the prognosis of patients skin cutaneous melanoma.